Retatrutide pen UK price guide — 2026

Retatrutide is a 39-amino-acid synthetic peptide with a fatty-acid side chain. Solid-phase peptide synthesis scales roughly with chain length and side-chain complexity, so retatrutide is meaningfully more expensive to produce than semaglutide (31 aa) or tirzepatide (39 aa with a simpler acylation). Layer on limited investigational supply — Eli Lilly has not licensed it, so there is no generic manufacturing scale — and the floor price is structurally higher than for approved GLP-1s.

The variables that move a UK quote inside the ranges above:

• HPLC purity — 90% vs 95% vs ≥98% is not a rounding difference; it is 8% less peptide by mass.
• CoA depth — batch-specific, mass-spec-confirmed, residual-solvent-tested CoAs cost more to produce.
• Format — pens carry hardware + cold-chain overhead; vials do not.
• Vial size — 15 mg vials undercut 5 mg vials on £/mg because packaging cost is a fixed overhead.
• UK cold-chain — UK-based dispatch adds cost but removes freeze-thaw risk on transit.
• Lot availability — investigational-grade material has irregular supply; scarce lots trade at a premium.

Headline price is not comparable across formats. Convert everything to £/mg at stated purity, then adjust for purity honestly:

The £80 vial looks cheaper. But without a batch CoA the 90% purity claim is unverified, and 10% of the vial mass is unknown material. The £110 vial with a published HPLC CoA at ≥98% purity is the honest baseline; anything below that price at the same quality is where the real bargains sit.

For a worked example of reading a certificate of analysis, see the HPLC & CoA guide.

Rough 2026 UK £/mg benchmarks at reference-grade purity (≥98% HPLC, batch CoA):

• Semaglutide — £3 – £6 / mg (10 mg vial)
• Tirzepatide — £5 – £9 / mg (10 mg vial)
• Retatrutide — £7 – £12 / mg (10 mg vial)
• Cagrilintide — £6 – £10 / mg (10 mg vial)

Retatrutide trades at roughly a 20–40% premium over tirzepatide per milligram. For the pharmacology behind the price gap, see retatrutide vs tirzepatide and semaglutide vs tirzepatide.

• No batch-specific CoA — purity claims are unverifiable without HPLC lot data.
• "Pharmaceutical grade" without a supporting analytical file — it is a marketing phrase, not a spec.
• £/mg materially below the ≥98% range without a CoA — usually under-purity or short-fill.
• No cold-chain on dispatch — reconstituted-ready pens especially need it.
• Medical framing (dosing schedules, weight-loss claims) on what is a research reagent — a compliance flag.

A reference-grade retatrutide vial ships with a batch-specific certificate of analysis (HPLC purity ≥98%, mass-spec identity, residual-solvent data) and UK-dispatched cold-chain. The research library references peptidesuk4u.co.uk, which publishes lot-level HPLC CoAs alongside every retatrutide listing — including their retatrutide pen (UK) — so the £/mg calculation above can be done honestly against a real spec sheet.

For the full pharmacology, trial data, MHRA status and reconstitution protocol, work back to the Retatrutide UK guide. For dose maths, use the reconstitution calculator and dose conversion calculator.